NEW YORK, April 20, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on ATOS, PTN, QTNT, and AVDL which can be accessed for free by signing up to www.wallstequities.com/registration. On Thursday, April 19, 2018, US markets saw broad based losses
On Thursday, shares in Seattle, Washington headquartered Atossa Genetics Inc. recorded a trading volume of 720,443 shares. The stock ended the session 0.08% lower at $0.36. The Company's shares have gained 9.88% over the previous three months. The stock is trading below its 50-day moving average by 33.95%. Moreover, shares of Atossa Genetics, which focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the US, have a Relative Strength Index (RSI) of 33.84. Get the full research report on ATOS for free by clicking below at: www.wallstequities.com/registration/?symbol=ATOS
Cranbury, New Jersey-based Palatin Technologies Inc.'s stock closed the day 1.49% lower at $1.32 with a total trading volume of 4.31 million shares, which was above their three months average volume of 1.83 million shares. The Company's shares have advanced 30.69% in the past month, 49.32% in the previous three months, and 265.55% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 23.57% and 67.46%, respectively. Additionally, shares of Palatin Technologies, which develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the US, have an RSI of 58.74. Free research on PTN can be accessed at: www.wallstequities.com/registration/?symbol=PTN
Shares in Penicuik, the UK-based Quotient Ltd recorded a trading volume of 204,746 shares. The stock ended yesterday's trading session 6.46% lower at $4.49. The Company's shares have advanced 20.70% over the previous three months. The stock is trading below its 50-day moving average by 5.60%. Furthermore, shares of Quotient, which develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide, have an RSI of 47.27. Sign up today for the free research report on QTNT at: www.wallstequities.com/registration/?symbol=QTNT
Avadel Pharmaceuticals PLC's stock finished Thursday's session 1.65% lower at $7.16 with a total trading volume of 83,618 shares. The Company's shares have advanced 3.02% in the last month. The stock is trading below its 50-day moving average by 7.37%. Additionally, shares of Avadel Pharma, which engages in drug delivery and formulation development to create safer and more efficacious pharmaceutical products, have an RSI of 45.57. Wall St. Equities' research coverage also includes the downloadable free report on AVDL at: www.wallstequities.com/registration/?symbol=AVDL
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-healthcare-equities----atossa-genetics-palatin-technologies-quotient-and-avadel-pharma-300633598.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All